Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01081132 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01081132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
September 19, 2011
Completion date
May 16, 2013
Enrollment
314 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder